.From the report, Co formulation a key for Opthea and will ultimately lead to OPT owning a new patent
. "The proceeds of the financing will primarily be used to
progress OPT-302 into the Phase 3 clinical program and to
develop a co-formulation of OPT-302 with a biosimilar antiVEGF-A therapy. We believe that a co-formulated OPT-302
and VEGF-A inhibitor product has the potential to be a marketleading treatment for wet AMD that offers the convenience
of a single-injection to achieve broader inhibition of the VEGF
signalling pathway, including VEGF-A, VEGF-C and VEGF-D."
- Forums
- ASX - By Stock
- Ann: Opthea Half Year Report and Accounts
.From the report, Co formulation a key for Opthea and will...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
(20min delay)
|
|||||
Last
40.0¢ |
Change
0.015(3.90%) |
Mkt cap ! $486.2M |
Open | High | Low | Value | Volume |
39.0¢ | 40.5¢ | 38.5¢ | $264.1K | 666.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 37687 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.0¢ | 18035 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
27 | 46592 | 0.400 |
12 | 108801 | 0.395 |
4 | 51453 | 0.390 |
9 | 235600 | 0.385 |
14 | 362765 | 0.380 |
Price($) | Vol. | No. |
---|---|---|
0.405 | 43365 | 8 |
0.410 | 198020 | 12 |
0.415 | 44669 | 8 |
0.420 | 414727 | 9 |
0.425 | 18900 | 1 |
Last trade - 11.08am 24/07/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online